New drug duo aims to tame High-Risk MDS
NCT ID NCT03564873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs—omacetaxine and azacitidine—given together to people with untreated high-grade myelodysplastic syndromes (MDS), a serious bone marrow condition. The first part finds the safest dose of omacetaxine, and the second part checks how many patients achieve remission. About 28 adults will take part, receiving the drugs for 7 days each month.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omacetaxine and azacitidine
What this could lead to
If successful, this combination could offer a new treatment option for people with high-grade myelodysplastic syndromes, potentially improving remission rates.
What could go wrong
This is a small, early-phase trial (Phase 1/2) with only 28 participants, so results may not apply broadly. The drugs can cause side effects like low blood counts and infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universtiy of Colorado Denver
Aurora, Colorado, 80045, United States